The fall of solanezumab late last year, followed by verubecestat in February, sent tremors through the Alzheimer's research community and wiped billions from the share prices of those biologics’ respective developers - Eli Lilly (NYSE: LLY) and Merck & Co (NYSE: MRK).
Neither event impacted the share price of North Carolina-based vTv Therapeutics (Nasdaq: VTVT), whose lead candidate azeliragon uniquely targets RAGE, a receptor in the brain which chief medical officer Larry Altsteil believes is key to the pathology of neurodegeneration.
Talking to The Pharma Letter at the Alzheimer’s Association International Conference in London, Dr Altsteil explains that "if there's a failure in one Abeta program, there's always a shudder of doubt that goes through the remaining programs in that space.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze